2025
Network structure of psychotic symptoms and childhood trauma in first-episode versus treatment-resistant schizophrenia
Liu Z, Wang X, Deng H, Huang J, Wang J, Chen W, Yang K, Li W, Chen S, Xie T, Liu R, Tian L, Yang F, Tian B, Li Y, Li C, Tan Y. Network structure of psychotic symptoms and childhood trauma in first-episode versus treatment-resistant schizophrenia. Journal Of Psychiatric Research 2025, 185: 31-39. PMID: 40147152, DOI: 10.1016/j.jpsychires.2025.03.037.Peer-Reviewed Original ResearchTreatment-resistant schizophrenia patientsTreatment-resistant schizophreniaFirst-episode schizophreniaPositive and Negative Syndrome ScaleChildhood traumaPsychotic symptomsInfluences psychotic symptomsNegative Syndrome ScaleChildhood Trauma QuestionnaireChildhood trauma experiencesSyndrome ScaleFirst-episodeTrauma QuestionnaireEmotional neglectTraumatic stressTrauma experiencesSchizophreniaSymptom patternsSexual abuseInfluence symptomsSymptom evolutionPartial correlationSymptomsClinical symptomsChildhoodConnectome-based predictive modeling of early and chronic psychosis symptoms
Foster M, Ye J, Powers A, Dvornek N, Scheinost D. Connectome-based predictive modeling of early and chronic psychosis symptoms. Neuropsychopharmacology 2025, 1-9. PMID: 40016363, DOI: 10.1038/s41386-025-02064-9.Peer-Reviewed Original ResearchConnectome-based predictive modelingPositive and Negative Syndrome ScalePsychosis symptomsSymptom networksSymptom severityBrain networksNeural correlates of CPResting-state functional magnetic resonance imagingFunctional magnetic resonance imagingNegative Syndrome ScaleIdentified group differencesPredicted effect sizeCorrelates of CPGeneral psychopathologyNegative symptomsPositive symptomsSyndrome ScaleFrontoparietal networkNeural correlatesVirtual lesion analysisGroup differencesConnectivity changesEffect sizeLesion analysisLongitudinal studyDeep multimodal representations and classification of first-episode psychosis via live face processing
Singh R, Zhang Y, Bhaskar D, Srihari V, Tek C, Zhang X, Noah J, Krishnaswamy S, Hirsch J. Deep multimodal representations and classification of first-episode psychosis via live face processing. Frontiers In Psychiatry 2025, 16: 1518762. PMID: 40134976, PMCID: PMC11934110, DOI: 10.3389/fpsyt.2025.1518762.Peer-Reviewed Original ResearchFirst-episode psychosisPositive and Negative Syndrome ScaleFunctional near-infrared spectroscopyGlobal Assessment of FunctioningEarly psychosisNeural correlates of social cognitionFirst-episode psychosis individualsNegative Syndrome ScaleBehavior recordsAssessment of FunctioningSevere psychiatric disordersSyndrome ScaleFace processingPsychosis symptomsNeural underpinningsSocial cognitionNeural correlatesPsychiatric disordersBrain activitySocial difficultiesNeurophysiological dysfunctionPsychosisNeural characteristicsMultimodal representationsAcquisition paradigm
2024
Sex-specific associations between 10-year cardiovascular risk, clinical symptoms and cognitive impairments in schizophrenia
Jin X, Lu C, Liu N, Li Y, Dong Y, Wang X, Li S, Li J. Sex-specific associations between 10-year cardiovascular risk, clinical symptoms and cognitive impairments in schizophrenia. Journal Of Neural Transmission 2024, 132: 313-322. PMID: 39387913, DOI: 10.1007/s00702-024-02842-7.Peer-Reviewed Original ResearchPositive and Negative Syndrome ScaleRepeatable Battery for the Assessment of Neuropsychological StatusPsychiatric symptomsNegative symptomsCognitive functionSex differencesAssessment of Neuropsychological StatusPANSS total scoreNegative Syndrome ScaleFramingham risk scoreSignificant sex differencesSyndrome ScalePsychopathology scoresImmediate memoryNeuropsychological statusCardiovascular riskSCZTotal scoreCognitive impairmentCardiovascular diseaseSex-specific associationsFasting venous blood samplesHigher Framingham risk scoreGlycolipid metabolism indexesSymptomsEfficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders. A systematic review and meta-analysis of individual patient data
Lochmann van Bennekom M, IntHout J, Gijsman H, Akdede B, Yağcıoğlu A, Barnes T, Galling B, Gueorguieva R, Kasper S, Kreinin A, Nielsen J, Nielsen R, Remington G, Repo-Tiihonen E, Schmidt-Kraepelin C, Shafti S, Xiao L, Correll C, Verkes R. Efficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders. A systematic review and meta-analysis of individual patient data. Schizophrenia Research 2024, 272: 1-11. PMID: 39142215, DOI: 10.1016/j.schres.2024.07.035.Peer-Reviewed Original ResearchClinical Global Impression ScaleSchizophrenia spectrum disordersPositive and Negative Syndrome ScaleBaseline PANSS total scoreAntipsychotic polypharmacyPANSS total scoreTotal scorePositive symptomsPsychotic patientsPositive and Negative Syndrome Scale positive symptom subscaleNegative symptom subscale scoreSubgroup of psychotic patientsBaseline positive symptomsExtrapyramidal side effectsNegative Syndrome ScalePositive symptom subscaleSecond-generation antipsychoticsGlobal Impression ScaleModerators of efficacySeverely psychotic patientsStudy-level moderatorsStudy discontinuationSymptom subscale scoresAntipsychotic monotherapySyndrome ScaleDisentangling negative and positive symptoms in schizophrenia and autism spectrum disorder
Corbera S, Wexler B, Bell M, Pittman B, Pelphrey K, Pearlson G, Assaf M. Disentangling negative and positive symptoms in schizophrenia and autism spectrum disorder. Schizophrenia Research 2024, 271: 1-8. PMID: 39002525, PMCID: PMC11384336, DOI: 10.1016/j.schres.2024.07.002.Peer-Reviewed Original ResearchAutism spectrum disorderPositive and Negative Syndrome ScaleAutism Diagnostic Observation Schedule-GenericExperiential negative symptomsPositive symptomsNegative symptomsExploratory factor analysisSpectrum disorderNegative Syndrome ScaleTarget negative symptomsSyndrome ScaleDiscriminant function analysisSZ relativesAssociated with quality of lifeSchizophreniaSocial skillsSocial functioningDiagnostic classificationAutismFactor analysisAssociated with qualityPredictor of diagnosisSymptomsDisordersQuality of lifeRelationship between plasma TNF-α levels and agitation symptoms in first episode patients with schizophrenia
Wang X, Chen W, Gou M, Li W, Li N, Tong J, Zhou Y, Xie T, Yu T, Feng W, Li Y, Chen S, Tian B, Tan S, Wang Z, Pan S, Luo X, Zhang P, Huang J, Tian L, Li C, Tan Y. Relationship between plasma TNF-α levels and agitation symptoms in first episode patients with schizophrenia. BMC Psychiatry 2024, 24: 480. PMID: 38956509, PMCID: PMC11218378, DOI: 10.1186/s12888-024-05796-y.Peer-Reviewed Original ResearchConceptsPositive and Negative Syndrome ScalePlasma TNF-a levelsAgitation symptomsPANSS-ECEpisode patientsTNF-a levelsPositive and Negative Syndrome Scale total scorePANSS-EC scoreNegative Syndrome ScaleSymptoms of schizophreniaPathophysiology of schizophreniaEnzyme-linked immunosorbent assayTNF-aR1 levelSyndrome ScalePlasma levels of tumor necrosis factor-alphaLevels of tumor necrosis factor-alphaSchizophreniaTotal scoreTumor necrosis factor-alphaNecrosis factor-alphaPlasma TNF-aHealthy controlsFEPImmune abnormalitiesSex differences in correlates of suicide attempts in Chinese Han first‐episode and drug‐naïve major depressive disorder with comorbid subclinical hypothyroidism: A cross‐sectional study
Tian X, Liu X, Bai F, Li M, Qiu Y, Jiao Q, Li J, Zhang X. Sex differences in correlates of suicide attempts in Chinese Han first‐episode and drug‐naïve major depressive disorder with comorbid subclinical hypothyroidism: A cross‐sectional study. Brain And Behavior 2024, 14: e3578. PMID: 38844426, PMCID: PMC11156525, DOI: 10.1002/brb3.3578.Peer-Reviewed Original ResearchConceptsPositive and Negative Syndrome ScaleHamilton Depression ScaleHamilton Anxiety ScaleFEDN MDD patientsMDD patientsSuicide attemptsSex differencesDepressive disorderFirst-episodeFactors associated with suicide attemptsRisk of suicide attemptNegative Syndrome ScaleMajor depressive disorderHamilton Depression Scale scoresHamilton Anxiety Scale scoresThyroid peroxidase antibodySubclinical hypothyroidismIncreased suicide attemptsInvestigate sex differencesSignificant sex differencesSyndrome ScalePositive subscaleIncreased riskAnxiety ScaleFEDNBelief Updating, Childhood Maltreatment, and Paranoia in Schizophrenia-Spectrum Disorders
Sloan A, Kittleson A, Torregrossa L, Feola B, Rossi-Goldthorpe R, Corlett P, Sheffield J. Belief Updating, Childhood Maltreatment, and Paranoia in Schizophrenia-Spectrum Disorders. Schizophrenia Bulletin 2024, sbae057. PMID: 38701234, DOI: 10.1093/schbul/sbae057.Peer-Reviewed Original ResearchSchizophrenia spectrum disordersExposure to childhood maltreatmentPositive and Negative Syndrome ScaleChildhood Trauma QuestionnaireChildhood maltreatmentHierarchical Gaussian FilterBelief updatingProbabilistic reversal learningNegative Syndrome ScaleSyndrome ScaleNonpsychiatric controlsReversal learningSchizophrenia spectrumCumulative maltreatmentTrauma QuestionnaireDeprivation exposureGreen et al.ParanoiaConferring riskMaltreatmentPrior expectationsDisordersIndirect effectsChildhoodBeliefsThe influence of gender-specific factors influencing severe anxiety in psychotic major depression: role of thyroid hormones and depression severity
Luo G, Jing Y, Yang J, Wang S, Xuekelaiti Z, Yao C, Gao Y, Chen H, Sun D, Li J, Zhang X. The influence of gender-specific factors influencing severe anxiety in psychotic major depression: role of thyroid hormones and depression severity. Journal Of Neural Transmission 2024, 131: 833-845. PMID: 38693463, DOI: 10.1007/s00702-024-02781-3.Peer-Reviewed Original ResearchHamilton Depression Rating ScalePositive and Negative Syndrome ScaleHamilton Depression Rating Scale scoresClinical Global Impressions-SeverityHamilton Anxiety Rating ScaleDepression severitySevere anxietyMDD patientsMajor depressionPMD patientsNon-psychotic MDD patientsRating ScaleThyroid-stimulating hormoneNegative Syndrome ScalePsychotic major depressionDepression Rating ScaleThyroid-stimulating hormone levelsAnxiety Rating ScaleIncreased depression severityAssociated with anxietyNo significant gender differencesSyndrome ScalePrevalence of severe anxietyPsychotic symptomsDepressive disorderEfficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review
Leber A, Ramachandra R, Ceban F, Kwan A, Rhee T, Wu J, Cao B, Jawad M, Teopiz K, Ho R, Le G, Ramachandra D, McIntyre R. Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review. Expert Opinion On Pharmacotherapy 2024, 25: 467-476. PMID: 38515004, DOI: 10.1080/14656566.2024.2334424.Peer-Reviewed Original ResearchPositive and Negative Syndrome ScalePANSS total score changeTotal score changeBaseline to week 5Randomized controlled trialsNegative Syndrome ScaleSchizophrenia spectrum disordersPlacebo groupScore changesSyndrome ScaleTreatment of adultsSpectrum disorderSchizophreniaXanomelineWeek 5Dry mouthClinical Trials RegistryTreatment avenuesPlaceboSide effectsPreclinical trialsTrials RegistryControlled trialsPRISMA guidelinesSystematic reviewWork Performance and Its Clinical Correlates in Patients With Chronic Mental Illness: The Chinese Version of Vocational Cognitive Rating Scale and the Work Behavior Inventory
Wang Y, Liu C, Chen K, Wu Y, Yen Y, Bell M, Chien Y. Work Performance and Its Clinical Correlates in Patients With Chronic Mental Illness: The Chinese Version of Vocational Cognitive Rating Scale and the Work Behavior Inventory. Psychiatric Rehabilitation Journal 2024, 47: 81-90. PMID: 37956062, DOI: 10.1037/prj0000590.Peer-Reviewed Original ResearchWork Behavior InventoryClinical correlatesCognitive Rating ScaleComprehensive Occupational Therapy Evaluation ScaleAffective symptomsMental illnessNegative symptomsRating ScaleGreater affective symptomsChronic mental illnessSevere mental illnessPersonalized rehabilitation programsChinese versionNegative Syndrome ScalePsychometric propertiesGood convergent validityTest-retest reliabilityClinical trialsChronic patientsRehabilitation programFunction assessmentSyndrome ScaleBehavior InventoryOccupational functionSymptomsCorrelation of allostatic load and perceived stress with clinical features in first-episode schizophrenia
Zhou Y, Wang L, Yang K, Huang J, Li Y, Li W, Zhang P, Fan F, Yin Y, Yu T, Chen S, Luo X, Tan S, Wang Z, Feng W, Tian B, Tian L, Li C, Tan Y. Correlation of allostatic load and perceived stress with clinical features in first-episode schizophrenia. Journal Of Psychiatric Research 2024, 172: 156-163. PMID: 38382239, DOI: 10.1016/j.jpsychires.2024.02.025.Peer-Reviewed Original ResearchFirst-episode schizophreniaCalgary Depression Scale for SchizophreniaPositive and Negative Syndrome ScalePerceived stressPositive symptomsAllostatic loadPSS scoresSeverity of positive symptomsClinical features of schizophreniaNegative Syndrome ScaleFeatures of schizophreniaChronic physiological stressAssociated with depressive symptomsEtiology of schizophreniaAssess subjective stressOccurrence of schizophreniaHealthy controlsPerceived Stress Scale-14Clinical featuresCDSS scoresSyndrome ScaleDepressive symptomsSchizophreniaSubjective stressStressor type
2023
Prevalence, risk factors and clinical correlates of glucose disturbances in a large sample of Han Chinese patients with first-episode drug-naïve major depressive disorder
Chen S, Wu Y, Li S, Li J, Lang X, Zhang X. Prevalence, risk factors and clinical correlates of glucose disturbances in a large sample of Han Chinese patients with first-episode drug-naïve major depressive disorder. European Archives Of Psychiatry And Clinical Neuroscience 2023, 274: 549-557. PMID: 36884047, DOI: 10.1007/s00406-023-01581-2.Peer-Reviewed Original ResearchConceptsFirst-episode drug-naiveFirst-episode drug-naive MDD patientsMajor depressive disorderMajor depressive disorder patientsHamilton Anxiety Rating ScalePositive and Negative Syndrome ScaleMDD patientsPsychotic symptomsDepressive disorderSuicide attemptsHAMD scoresComorbidity of major depressive disorderHamilton Anxiety Rating Scale scoresSample of Han Chinese patientsNegative Syndrome ScalePositive symptom subscaleAnxiety Rating ScaleAssociated with HAMD scoreSevere depressive symptomsBody mass indexHigher suicide attemptsGlucose disturbancesFEDN patientsSyndrome ScaleAcute early phaseGender differences in outcomes of early intervention services for first episode psychosis
Hong S, Bennett D, Rosenheck R. Gender differences in outcomes of early intervention services for first episode psychosis. Early Intervention In Psychiatry 2023, 17: 715-723. PMID: 36623822, PMCID: PMC10329725, DOI: 10.1111/eip.13367.Peer-Reviewed Original ResearchConceptsFirst-episode psychosisEarly intervention servicesClinical trialsEpisode psychosisInitial Schizophrenia Episode-Early Treatment Program (RAISE-ETP) studyEarly interventionIntervention servicesRandomized clinical trialsComorbid substance useUS clinical trialsSignificant gender differencesNegative Syndrome ScaleBaseline gender differencesGender differencesSchizophrenia spectrum disordersAntipsychotic exposureUsual careBaseline characteristicsMood symptomsDepression subscalePsychotic disordersMasked evaluatorsSchizoaffective disorderSyndrome ScaleSecondary analysis
2022
Abnormal cortisol profile during psychosocial stress among patients with schizophrenia in a Chinese population
Zhu X, Zhu Y, Huang J, Zhou Y, Tong J, Zhang P, Luo X, Chen S, Tian B, Tan S, Wang Z, Han X, Tian L, Li CR, Hong LE, Tan Y. Abnormal cortisol profile during psychosocial stress among patients with schizophrenia in a Chinese population. Scientific Reports 2022, 12: 18591. PMID: 36329219, PMCID: PMC9633605, DOI: 10.1038/s41598-022-20808-1.Peer-Reviewed Original ResearchConceptsNegative affect scoresAffect scoresPaced Auditory Serial Addition TaskAuditory Serial Addition TaskMirror-Tracing Persistence TaskSerial Addition TaskNegative Affect ScheduleChallenge taskNegative emotionsAddition taskPersistence taskCortisol responseSignificant interactionSalivary cortisol levelsNegative Syndrome ScaleCortisol profilesCortisol levelsSaliva cortisol levelsPsychological stressPsychosocial stressHealthy volunteersEmotionsSyndrome ScaleTaskAdrenal axis dysfunctionAssociations of the serum kynurenine pathway metabolites with P50 auditory gating in non-smoking patients with first-episode schizophrenia
Yang Q, Zhang Y, Yang K, Niu Y, Fan F, Chen S, Luo X, Tan S, Wang Z, Tong J, Yang F, Li C, Tan Y. Associations of the serum kynurenine pathway metabolites with P50 auditory gating in non-smoking patients with first-episode schizophrenia. Frontiers In Psychiatry 2022, 13: 1036421. PMID: 36339840, PMCID: PMC9632432, DOI: 10.3389/fpsyt.2022.1036421.Peer-Reviewed Original ResearchFirst-episode schizophreniaP50 auditory gatingNon-smoking patientsHealthy controlsAuditory gatingSerum kynurenineSerum levelsS2/S1 ratioAcid levelsKynurenine pathway metabolitesFirst-episode patientsNegative Syndrome ScaleKynurenine acidEpisode patientsNeuroactive metabolitesKynurenine pathwayPatientsS1 ratioSyndrome ScaleCognitive impairmentS1-S2SchizophreniaPathway metabolitesS1 amplitudeKynurenineSublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial.
Citrome L, Preskorn SH, Lauriello J, Krystal JH, Kakar R, Finman J, De Vivo M, Yocca FD, Risinger R, Rajachandran L. Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial. The Journal Of Clinical Psychiatry 2022, 83 PMID: 36198061, DOI: 10.4088/jcp.22m14447.Peer-Reviewed Original ResearchConceptsAcute agitationHours postdoseSchizoaffective disorderTotal scorePrimary efficacy endpointPlacebo-controlled studyAdrenergic receptor agonistFifth Edition criteriaNegative Syndrome ScaleDexmedetomidine groupOral hypoesthesiaStudy medicationDry mouthEfficacy endpointOrthostatic hypotensionRandomized PlaceboAdverse eventsReceptor agonistEdition criteriaDexmedetomidineMean changePEC scoresPlaceboSyndrome ScaleUS sitesLongitudinal association between exposome score for schizophrenia and clinical features: results from the Athens First-Episode Psychosis Research Study
Erzin G, Pries L, Dimitrakopoulos S, Ralli I, Xenaki L, Soldatos R, Vlachos I, Selakovic M, Foteli S, Kosteletos I, Nianiakas N, Mantonakis L, Rizos E, Kollias K, Os J, Guloksuz S, Stefanis N. Longitudinal association between exposome score for schizophrenia and clinical features: results from the Athens First-Episode Psychosis Research Study. European Psychiatry 2022, 65: s760-s760. PMCID: PMC9567635, DOI: 10.1192/j.eurpsy.2022.1963.Peer-Reviewed Original ResearchPANSS total scoreFirst-episode psychosisClinical featuresES-SCZTotal scoreIllness coursePsychosis developmentLongitudinal associationsEnvironmental exposuresTime interactionNegative Syndrome ScaleExposome scoreEpisode psychosisSyndrome ScaleSymptom severitySchizophreniaEnvironmental predispositionMultilevel regression analysisScoresRegression analysisFollowPrevious reportsBaselineAssociationCurrent studyBelief Updating and Paranoia in Individuals With Schizophrenia
Sheffield JM, Suthaharan P, Leptourgos P, Corlett PR. Belief Updating and Paranoia in Individuals With Schizophrenia. Biological Psychiatry Cognitive Neuroscience And Neuroimaging 2022, 7: 1149-1157. PMID: 35430406, PMCID: PMC9827723, DOI: 10.1016/j.bpsc.2022.03.013.Peer-Reviewed Original ResearchConceptsBelief updatingThought contentPersecutory delusionsUnusual thought contentHierarchical Gaussian FilterMeasures of anxietyPrior beliefsSignificant indirect effectHealthy control participantsCognitive mechanismsProbabilistic reversalPersecutory beliefsParanoia continuumWorry QuestionnaireNegative Syndrome ScaleControl participantsParanoiaModel implicatingIndirect effectsSymptom Rating ScaleSyndrome ScaleWorryBeliefsSchizophreniaSignificant worry
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply